Two generic drugs that are key components in many chemotherapy regimens for several different types of cancer are now in such short supply that the FDA, in May 2023, announced that it would allow temporary importation of a non-approved version of one of the medications, cisplatin, from a specific manufacturer and distributor in China.
Despite that policy shift, many cancer centers are still having to delay patients’ treatments, put off new starts or even consider prioritizing which